计算方法阐明胰岛素NPH配方中的胰岛素-蛋白质胺结合相互作用和动态
Ketan Kumar Rohilla1, Manoj Kumar Pandey1
1Department of Chemistry, Indian Institute of Technology Ropar, Rupnagar, Punjab 140001, India.
ACS omega
|February 5, 2024
概括
这项研究揭示了蛋白胺如何与胰岛素NPH结合,形成稳定的复合物. 生物信息学模拟确定了关键相互作用,解释了中介作用胰岛素.
科学领域:
- 生物化学 生物化学
- 结构生物学 结构生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 胰岛素NPH是一种中间作用胰岛素配方.
- 它的长时间作用归因于胰岛素-原胺复合体.
- 蛋白胺与胰岛素的确切结合机制尚不清楚.
研究的目的:
- 阐明与胰岛素R6六合体相互作用的原胺的结合表位和模式.
- 使用计算方法计算胰岛素-原胺复合物的结合点和能量.
主要方法:
- 利用生物信息学工具,包括分子对接和200 ns分子动力学 (MD) 模拟.
- 将四种天然存在的蛋白质胺与胰岛素R6六合体结合.
- 分析了结合相互作用 (结合,疏水性,静电性) 和估计的结合能量.
主要成果:
- 富含氨酸的蛋白胺与胰岛素六合体表面结合.
- 结合是由结合,疏水性和静电相互作用介导的,由负结合能支持.
- 胰岛素六合体结构保持稳定,在原胺中存在动态终端残留物.
结论:
- 质氨酸与胰岛素R6的结合以特定的相互作用和负结合能量为特征.
- 胰岛素六合体在复合体内表现出动态稳定性.
- 计算方法有效地模拟了胰岛素和原胺蛋白相互作用的动态和能量.
相关概念视频
Insulin Formulations: Types and Delivery
197
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
197
Insulin: Biosynthesis, Chemistry, and Preparation
382
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
382
Physiological Pharmacokinetic Models: Assumption with Protein Binding
45
Physiological models with protein binding in pharmacokinetics offer a sophisticated approach to understanding drug disposition. These models consider drug-protein interactions, enabling them to effectively predict drug concentrations in different organs and tissues. This precision aids in accurate drug dosing, providing a significant advantage over conventional models. A key process within these models is equilibration, which ensures that drug concentrations achieve a steady state within the...
45
Protein-Drug Binding: Determination Methods
184
Determining protein-drug binding can be achieved through indirect and direct methods, each providing valuable insights into the interaction between proteins and drugs.
Indirect methods involve isolating the bound drug from its free form in biological samples such as blood, serum, or plasma. These techniques aim to measure the percentage of drugs bound to proteins. Equilibrium dialysis is a commonly used method where the free drug concentration at equilibrium is measured by separating the bound...
Indirect methods involve isolating the bound drug from its free form in biological samples such as blood, serum, or plasma. These techniques aim to measure the percentage of drugs bound to proteins. Equilibrium dialysis is a commonly used method where the free drug concentration at equilibrium is measured by separating the bound...
184
Insulin: Dosing Regimen and Adverse Effects
174
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
174
Oral Hypoglycemic Agents: Glinides
154
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
154


